Pharmaceutical companies entering new geographies face one of the most complex and regulated market entry environments in any industry – requiring product registration, pricing and reimbursement negotiation, distribution establishment, and healthcare professional engagement across distinct regulatory frameworks in each market. GreyRadius helps pharmaceutical companies validate market opportunity, navigate registration processes, establish distribution, and raise capital – grounded in primary research with physicians, pharmacists, hospital procurement teams, and regulatory authorities.
Why now? Generic medicine patent cliffs over 2024–2028 are creating significant market entry opportunities for generic manufacturers across Southeast Asia, South Asia, and the Gulf. Biosimilar launches in oncology, immunology, and diabetes are creating new commercial opportunities in markets where originator biologics have been too expensive for mass-market reimbursement.
Pharmaceutical spending in Southeast Asia is projected to reach $50B by 2027 – with generic medicines, over-the-counter healthcare, and government insurance scheme reimbursement driving the majority of volume growth.
Biologics and biosimilars are the fastest-growing pharmaceutical segment globally – with oncology, immunology, and diabetes biosimilars achieving commercial launches in Southeast Asia and South Asia for the first time.
Digital prescription platforms are transforming pharmaceutical distribution – e-prescription systems and digital pharmacy platforms are creating new data-driven channels for pharmaceutical companies to track and influence prescribing.
Local manufacturing incentives are creating investment opportunities – India's PLI scheme, Indonesia's domestic pharmaceutical incentives, and Gulf localisation programmes all support pharmaceutical manufacturing investment.
If you recognise your situation below, we can help.
Pharmaceutical market opportunity assessment
You need to assess prescription volume potential, payer reimbursement dynamics, and competitive landscape before committing registration and commercial investment.
Regulatory registration pathway
You need to understand product registration requirements, dossier preparation timelines, and approval processes in your target market.
Distribution and channel strategy
You need to identify and establish relationships with pharmaceutical wholesalers, hospital distributors, and retail pharmacy chains in a new market.
Healthcare professional engagement strategy
You need a medical affairs and commercial strategy for engaging physicians, pharmacists, and hospital formulary committees in a new market.
Raising capital for pharma expansion
You are raising investment for pharmaceutical market entry or a new drug development programme and need a pitch book grounded in market demand data.
Competitive intelligence
You need to understand how competing pharmaceutical companies are positioned, priced, and winning prescriptions in your target therapeutic segment.
Every engagement is grounded in primary research and delivers a measurable outcome.
Validate prescription demand and market opportunity for pharmaceutical products in a new market. Covers physician and pharmacist interviews, payer research, regulatory mapping, and a Go/Defer/Kill recommendation.
Learn more →Full financial and operational feasibility for pharmaceutical market entry. Covers prescription volume modelling, registration cost pathway, distribution economics, and investor-ready financial projections.
Learn more →End-to-end market entry for pharmaceutical companies. Regulatory registration pathway, distributor identification, HCP outreach strategy, and first-prescription or first-formulary milestone.
Learn more →Embedded GTM team for pharmaceutical companies. HCP outreach, hospital formulary development, distribution pipeline, and first-revenue milestone tracking.
Learn more →Investor-ready pitch books for pharmaceutical expansions. Prescription-demand-validated market sizing, competitive analysis, and investor identification.
Learn more →AI use-case prioritisation in pharma – from digital HCP engagement and prescription analytics to supply chain optimisation and pharmacovigilance automation.
Learn more →80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Healthcare · Market Entry
Healthcare · GTM Execution
Healthcare · Assessment
Both. We work with originator companies on market assessment and commercial strategy, and with generic manufacturers on market entry, registration pathway, and distribution establishment.
Southeast Asia, South Asia, and the Gulf – markets with significant pharmaceutical demand growth and varying regulatory complexity.
Typically 8–12 weeks given the complexity of regulatory pathway mapping and prescriber demand research.
Yes. Payer dynamics analysis and reimbursement pathway mapping are part of our pharmaceutical market entry methodology.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Southeast Asia, South Asia, Gulf.
